mayo clinic glp-1 program medications: expert shares insights | Mayo Clinic Business Development posted on the topic GLP1 and GIP Receptor Agonists:
Description
Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes
It could be only about weight loss or weight maintenance, or you may also need the drug to improve other health issues like type 2 diabetes, heart disease, or metabolic syndrome
People with obesity tend to have a poorer response to some disease-modifying therapies, particularly older first-line treatments, compared with people at a healthier weight, she says
I was skeptical, but Im losing a pound a day
Published clinical trial data generally shows higher average weight loss with brand-name tirzepatide than with brand-name semaglutide in controlled conditions - approximately 20.9% body weight reduction with tirzepatide in the SURMOUNT-1 trial versus approximately 14.9% with semaglutide in the STEP-1 trial
10.1161/CIRCULATIONAHA.117.028136 [DOI] [PubMed] [Google Scholar] 38.Elashoff M, Matveyenko A, Gier B, Elashoff R, Butler P
